Hydrogen peroxide topical - Aclaris Therapeutics

Drug Profile

Hydrogen peroxide topical - Aclaris Therapeutics

Alternative Names: A 101 40%; A 101 45%; A-101 - Aclaris; ESKATA; Oxydol; V-101 - Aclaris

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aclaris Therapeutics
  • Class Antibacterials; Antiseptics; Disinfectants; Peroxides; Skin disorder therapies
  • Mechanism of Action Oxidoreductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Seborrhoeic keratosis

Highest Development Phases

  • Marketed Seborrhoeic keratosis
  • Phase II Warts

Most Recent Events

  • 06 Apr 2018 Hydrogen peroxide topical licensed to Cipher Pharmaceuticals in Canada
  • 06 Apr 2018 Launched for Seborrhoeic keratosis in USA (Topical) before April 2018 - First global launch
  • 23 Mar 2018 Aclaris Therapeutics files for patent protection for the use of high-concentration hydrogen peroxide in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top